Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HeraMEDASX:HMD -7.69% Receivables Turnover is 0.65 as of Dec. 2025. The stock has 2 warning signs investors should review. Among 813 Medical Devices & Instruments companies, HeraMED ranks worse than 96.19% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. HeraMED's Revenue for the
six
months ended in Dec. 2025 was A$0.15 Mil. HeraMED's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$0.24 Mil.
Hence, HeraMED's Receivables Turnover for the
six
months ended in Dec. 2025 was 0.65.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
HeraMED Receivables Turnover Related Terms
HeraMED Receivables Turnover Historical Data
* Premium members only.
The historical data trend for HeraMED's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:HMD vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, HeraMED's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeraMED Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HeraMED's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where HeraMED's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeraMED (ASX:HMD) has a Receivables Turnover of 0.65 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on HeraMED and its competitors. According to the industry distribution chart, HeraMED ranks #782 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 96.2%.
Is HeraMED's Receivables Turnover too high?
HeraMED's current Receivables Turnover is 0.65. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. HeraMED's value of 0.65 is 88.2% below this industry median. Based on the distribution chart, HeraMED ranks #782 out of 813 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does HeraMED's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HeraMED ranks #782 out of 813 companies for Receivables Turnover. This places HeraMED in the lower half of its industry. The industry median Receivables Turnover is 5.51. HeraMED's value of 0.65 is 88.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HeraMED's current Receivables Turnover of 0.65 is 88.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on HeraMED and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeraMED's current Receivables Turnover is 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeraMED stock overvalued right now?
Based on GuruFocus' analysis, HeraMED (ASX:HMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.04 — trading 80% above its estimated fair value. The current Receivables Turnover is 0.65 and 88.2% below the Medical Devices & Instruments industry median of 5.51. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For HeraMED (ASX:HMD), the current Receivables Turnover is 0.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeraMED Ltd is a medical data and technology company providing the digital transformation of maternity care by revolutionizing the prenatal and postpartum experience with its hybrid maternity care platform. It offers a proprietary platform that utilizes hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence. Its offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, and allow healthcare professionals to provide the care and enable early detection and prevention of potential risks.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HMD has been successfully added to your 
